-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

163 The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) TransfusionsClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 112. Thalassemia and Globin Gene Regulation: Clinical
Hematology Disease Topics & Pathways:
Diseases, Therapies, thalassemia, Hemoglobinopathies, Clinically relevant
Saturday, December 1, 2018: 2:00 PM
Room 30D (San Diego Convention Center)

Maria Domenica Cappellini, MD1, Vip Viprakasit, MD, DPhil2*, Ali Taher, MD PhD3, Pencho Georgiev, MD4,5*, Kevin H. M. Kuo, MD, MSc, FRCPC6, Thomas D. Coates, MD7,8, Ersi Voskaridou, MD9*, Hong Keng Liew10*, Idit Pazgal-Kobrowski11*, Gianluca Forni12*, Silverio Perrotta13*, Abderrahim Khelif14*, Ashutosh Lal, MD15, Antonis Kattamis16, Efthymia Vlachaki17*, Raffaella Origa, MD18*, Yesim Aydinok19*, Mohamed Bejaoui20*, P. Joy Ho21, Lee Ping Chew22*, Ping Chong Bee23*, Soo Min Lim24*, Meng-Yao Lu25*, Adisak Tantiworawit26*, Penka Ganeva27*, Liana Gercheva28*, Farrukh Shah29*, Ellis J. Neufeld30, Abderrahmane Laadem, MD31, Jeevan K. Shetty32*, Jun Zou, MD PhD31*, Dimana Miteva, PhD32*, Tatiana Zinger, PhD32*, Peter G. Linde33, Matthew L. Sherman33, Olivier Hermine, MD PhD34,35*, John Porter, MA MD FRCP FRCPath36* and Antonio Piga37

1Fondazione IRCCS Ca’ Granda Policlinico Hospital, University of Milan, Milan, Italy
2Siriraj Hospital, Mahidol University, Bangkok, Thailand
3Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
4University Multiprofile Hospital for Active Treatment “Sveti Georgi”, and Medical University Plovdiv, Plovdiv, Bulgaria
5St George University Hospital for Active Treatment, Plovdiv, Bulgaria
6Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada
7Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA
8USC Keck School of Medicine, Los Angeles, CA
9Thalassemia and Sickle Cell Center of Laiko General Hospital, Athens, Greece
10Hospital Sultanah Bahiyah, Alor Setar, Malaysia
11Comprehensive Center of Thalassemia, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
12Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, Ospedale Galliera, Genoa, Italy
13Università della Campiana, Luigi Vanvitelli, Caserta, Italy
14Farhat Hached University Hospital, Sousse, Tunisia
15University of California San Francisco Benioff Children’s Hospital, Oakland, CA
16First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece
17Adult Thalassemia Unit, Hippokration Hospital, Thessaloniki, Greece
18University of Cagliari, Cagliari, Italy
19Department of Pediatric Hematology and Oncology, Ege University Hospital, Izmir, Turkey
20National Center of Bone Marrow Transplant and Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia
21Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia
22Hospital Umum, Kuching, Malaysia
23University of Malaya Medical Centre, Kuala Lumpur, Malaysia
24Sultanah Aminah Hospital, Johor Bahru, Malaysia
25National Taiwan University, Taipei City, Taiwan
26Division of Hematology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
27University Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria
28University Hospital St. Marina, Varna, Bulgaria
29Department of Haematology, Whittington Health NHS Trust, London, United Kingdom
30St. Jude Children's Research Hospital, Memphis, TN
31Celgene Corporation, Summit, NJ
32Celgene Corporation, Boudry, Switzerland
33Acceleron Pharma, Cambridge, MA
34Necker Hospital, Paris, France
35Imagine Institute, Paris, France
36Professor of Haematology and Consultant Haematologist, University College London; University College London Hospitals, London, United Kingdom
37Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

Introduction: β-thalassemia is an inherited hemoglobinopathy associated with an erythroid maturation defect characterized by ineffective erythropoiesis and impaired RBC maturation. Luspatercept is a first-in-class erythroid maturation agent under development to treat patients with β-thalassemia. Luspatercept binds to select TGFβ superfamily ligands to reduce aberrant Smad2/3 signaling and enhance late-stage erythropoiesis (Suragani RN, et al. Nat Med. 2014;20:408-14).

We report the results of a phase 3, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of luspatercept in adult β-thalassemia patients requiring regular RBC transfusions. ClinicalTrials.gov identifier: NCT02604433.

Methods: Eligible patients were aged ≥ 18 years; had β-thalassemia or hemoglobin (Hb) E/β‑thalassemia (compound β-thalassemia mutation and/or multiplication of α-globin genes was allowed); and required regular transfusions of 6–20 RBC units in the 24 weeks prior to randomization with no transfusion-free period ≥ 35 days during that time. Patients were randomized 2:1 to receive either luspatercept, at a starting dose level of 1.0 mg/kg with titration up to 1.25 mg/kg, or placebo, subcutaneously every 3 weeks for ≥ 48 weeks. Patients in both treatment arms continued to receive RBC transfusions and iron chelation therapy to maintain the same baseline Hb level.

The primary endpoint was a ≥ 33% reduction in transfusion burden (with a reduction of ≥ 2 RBC units) during weeks 13–24, when compared with a 12-week baseline period. Key secondary endpoints included: ≥ 33% reduction in RBC transfusion burden at weeks 37–48, ≥ 50% reduction in transfusion burden at weeks 13–24, ≥ 50% reduction in transfusion burden at weeks 37–48, and mean change in transfusion burden at weeks 13–24.

Achievement of ≥ 33% reduction in RBC transfusion burden over any consecutive 12 weeks on study was also evaluated.

Results: A total of 336 patients were randomized, of whom 332 were treated. Median age was 30 years (range 18–66) and 58% of patients were female. Patients received a median of 6 RBC units in the 12 weeks prior to treatment. 58% of patients in each arm had undergone splenectomy. B0/B0 genotype (classification according to the HbVar database) was observed in 68 of 224 (30.4%) and 35 of 112 (31.3%) patients in the luspatercept and placebo arms, respectively.

48 of 224 (21.4%) patients in the luspatercept arm achieved the primary endpoint versus 5 of 112 (4.5%) patients receiving placebo (odds ratio 5.79, P < 0.0001). 44 of 224 (19.6%) patients receiving luspatercept achieved a ≥ 33% reduction in RBC transfusion burden at weeks 37–48 compared with 4 of 112 (3.6%) patients receiving placebo (P < 0.0001). Of 224 patients receiving luspatercept, 17 (7.6%) and 23 (10.3%) achieved a ≥ 50% reduction in RBC transfusion burden at weeks 13–24 and 37–48, respectively, compared with 2 (1.8%) and 1 of 112 (0.9%) patients receiving placebo (P = 0.0303 and P = 0.0017, respectively). The difference of mean change from baseline in transfusion burden from week 13 to week 24 was 1.35 units (P < 0.0001).

158 of 224 (70.5%) patients receiving luspatercept achieved a ≥ 33% RBC transfusion reduction over any consecutive 12 weeks compared with 33 of 112 (29.5%) patients receiving placebo (P < 0.0001); statistically significant differences were also noted for all other transfusion burden reduction endpoints.

Adverse events (AEs) observed in the study were generally consistent with previously reported phase 2 data. Treatment-emergent AEs leading to dose delay or dose reduction were similar between treatment arms. No patient deaths were reported for those treated with luspatercept.

Conclusions: Treatment with luspatercept resulted in significant reductions in RBC transfusion burden in adults with transfusion-dependent β-thalassemia. Luspatercept was generally well tolerated in this patient population.

As of May 11, 2018, cutoff date.

Disclosures: Cappellini: Celgene Corporation: Membership on an entity's Board of Directors or advisory committees; Sanofi/Genzyme: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Vifor: Membership on an entity's Board of Directors or advisory committees. Viprakasit: Protagonist Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Taher: Protagonist Therapeutics: Consultancy; Novartis: Consultancy, Honoraria, Research Funding; Ionis Pharmaceuticals: Consultancy; La Jolla Pharmaceutical: Research Funding; Celgene Corp.: Research Funding. Georgiev: Alnylam: Consultancy. Coates: Celgene Corp.: Consultancy; ApoPharma: Consultancy, Honoraria; Vifor Pharma: Consultancy; Sangamo: Consultancy, Honoraria. Voskaridou: Acceleron: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corp: Membership on an entity's Board of Directors or advisory committees, Research Funding. Forni: Novartis: Research Funding; Roche: Research Funding; Celgene: Research Funding. Perrotta: Acceleron Pharma: Research Funding; Novartis: Research Funding. Lal: Celgene Corporation: Research Funding; Bluebird Bio: Research Funding; La Jolla Pharmaceutical Company: Consultancy, Research Funding; Insight Magnetics: Research Funding; Novartis: Research Funding; Terumo Corporation: Research Funding. Kattamis: ApoPharma: Honoraria; Vifor Pharma: Consultancy; CELGENE: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Vlachaki: Novartis: Honoraria. Origa: Cerus Corporation: Research Funding; Bluebird Bio: Consultancy; Novartis: Honoraria; Apopharma: Honoraria. Aydinok: Novartis: Research Funding, Speakers Bureau; La Jolla Pharmaceuticals: Research Funding; Cerus: Honoraria, Research Funding; CRISPR Tech: Other: DMC; Protagonist: Other: SSC; TERUMO: Research Funding; Celgene: Research Funding. Ho: Takeda: Honoraria, Other: travel to meeting; Novartis: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Celgene: Other: Travel to meeting. Chew: Celgene: Research Funding. Tantiworawit: Celgene: Honoraria, Research Funding, Speakers Bureau. Shah: Novartis: Honoraria, Speakers Bureau; Sobi/Apotex: Honoraria; Celgene Corp: Other: Steering committee; Roche: Other: Advisory board meeting. Neufeld: Celgene Corp.: Consultancy, Other: Steering committee; Acceleron Pharma: Consultancy. Laadem: Celgene: Employment, Equity Ownership. Shetty: Celgene: Employment, Equity Ownership. Zou: Celgene Corporation: Employment, Equity Ownership. Miteva: Celgene Corporation: Employment, Other: grants. Zinger: Celgene Corporation: Employment. Linde: AbbVie: Equity Ownership; Abbott Laboratories: Equity Ownership; Fibrogen: Equity Ownership; Acceleron Pharma: Employment, Equity Ownership. Sherman: Acceleron Pharma: Employment, Equity Ownership. Hermine: AB Science: Consultancy, Equity Ownership, Honoraria, Research Funding; Celgene Corporation: Research Funding; Hybrigenics: Research Funding; Erythec: Research Funding; Novartis: Research Funding. Porter: Protaganist: Other: Advisory Board; Bluebird Bio: Consultancy, Other: Advisory Board; Silence Therapeutics: Other: Advisory Board; Cerus: Honoraria; Novartis: Consultancy; Agios: Honoraria; Lajolla: Other: Advisory Board. Piga: La Jolla: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bluebird Bio: Honoraria; Apopharma: Honoraria, Research Funding; Celgene Corp: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Acceleron: Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH